Sputnik Light / Gamaleya Research Institute - LARVOL DELTA

Adenovirus-Based Single-Dose Vaccines for SARS-CoV-2: A Review. (PubMed, Front Biosci (Landmark Ed)) - "Clinical trials of these single-dose vaccines are commendable and have shown excellent safety and efficacy profiles. This review provides a summary of the development of single-dose vaccines against SARS-CoV-2."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

The Parameters of Long-Term Humoral Immunity Induced by a Single Injection of the Sputnik Light Vaccine Among Noninfected Volunteers and Those Infected with SARS-CoV-2. (PubMed, Acta Naturae) - "The findings indicate that single-shot vaccination with the Sputnik Light vaccine induces a durable (seroconversion 73% on day 180) and mature humoral immunity. Natural immunization as a result of the SARS-CoV-2 infection leads to significant changes in the studied parameters of post-vaccination immunity."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

EXPLORING THE POTENTIAL LINK: ISCHEMIC STROKE INCIDENCE FOLLOWING COVID-19 VACCINATION (WSC 2024) - "Like other types of vaccines, COVID-19 vaccines have their own local and systemic side effects, as well as other systemic complications, including neurological ones...Results A total of 1,585,014 people have been completed the full course of vaccination (minimum age 18 years, maximum 85 years) and 6,796,188 doses of vaccines have been used (Oxford/AstraZeneca 240,144 doses, ZF2001 3,411,125 doses, Sputnik V 257,593 doses, Moderna 1,132 121 doses, Pfizer/BioNTech 1,441,627 doses, Sinovac 251,146 doses, Sputnik Light 51,141 doses, Johnson&Johnson 11,291 doses)...Conclusions Given the risk of neurological complications is extremely rare (0.001%), vaccination is the only way to protect against COVID-19. At a time when the COVID-19 infection has enormous complications not only in the nervous system, but also in other systems, even death."

Cardiovascular • Hematological Disorders • Infectious Disease • Ischemic stroke • Novel Coronavirus Disease • Thrombosis

COVID-19 Vaccines Breakthrough Infections and Adverse Effects Reported by the Birzeit University Community in Palestine. (PubMed, Int J Gen Med) - "This study aimed to explore the type and severity of short-term adverse reactions associated with BNT162 (Pfizer-BioNTech), mRNA 1273 (Moderna), and viral vector vaccines and to compare the incidence of post-vaccination Covid-19 infection among the Birzeit University community in Palestine...The study included participants aged 18 years and older who were vaccinated with Pfizer, Moderna, Sputnik Light, or Sputnik v. A total of 558 participants who were administered COVID-19 vaccine were included in the study...Furthermore, the Pfizer/BioNTech COVID-19 vaccine group reported fewer commonly reported side effects (fever, chills, headache, fatigue, muscle pain, joint pain, nausea, and dizziness), followed by the Moderna and viral vector vaccines. Females and underweight participants experienced more adverse effects with both vaccines, and fewer common side effects were reported by all participants."

Adverse events • Journal • Fatigue • Infectious Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Novel Coronavirus Disease • Orthopedics • Pain • Respiratory Diseases

ASSESSING THE POTENTIAL NEUROLOGICAL IMPACT OF COVID-19 VACCINES: AN IN-DEPTH EXAMINATION OF REPORTED COMPLICATIONS (EAN 2024) - " A total of 1,585,014 people have been completed the full course of vaccination (minimum age 18 years, maximum 85 years) and 6,796,188 doses of vaccines have been used (Oxford/AstraZeneca 240,144 doses, ZF2001 3,411,125 doses, Sputnik V 257,593 doses, Moderna 1,132 121 doses, Pfizer/BioNTech 1,441,627 doses, Sinovac 251,146 doses, Sputnik Light 51,141 doses, Johnson&Johnson 11,291 doses)... Given the risk of neurological complications is extremely rare (0.001%), vaccination is the only way to protect against COVID-19. At a time when the COVID-19 infection has enormous complications not only in the nervous system, but also in other systems, even death."

Cardiovascular • CNS Disorders • Hematological Disorders • Infectious Disease • Ischemic stroke • Multiple Sclerosis • Novel Coronavirus Disease • Otorhinolaryngology • Thrombosis

Comparative Analysis of SARS-CoV-2 Antibody Responses across Global and Lesser-Studied Vaccines. (PubMed, Vaccines (Basel)) - "The vaccines under comparison include well-known ones like Pfizer (BNT162b2) and AstraZeneca (ChAdOx1-S), alongside less-studied vaccines including Soberana (Soberana 02), Abdala (CIGB-66), and Sputnik V/Sputnik Light...Overall, we found no evidence of waning in the antibody magnitude across vaccines. Our study supports the conclusion that populations with high infection rates still benefit substantially from vaccination."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Disparities in Anti-SARS-CoV-2 Reactivity According to Vaccines in the Era of Omicron in Cameroon (CROI 2024) - "Regarding COVID-19 vaccination, 67.5%(1652/2449) had received at least one dose (48.7% Pfizer, 24.8% Johnson&Johnson, 18.2% Moderna; 8.1% AstraZeneca, 4.8% Sinopharm and 0.2% Sputnik-light); among these, 55.0%(909/1652) were fully vaccinated and 37.1%(613/1652) received additional boost doses...The high-rate of COVID-19 antibodies suggests herd immunity at community-level in Cameroon, during the wide circulation of Omicron. Furthermore, vaccination with Pfizer appears with higher Covid-19 antibody response, supporting the need for vaccine update with novel variants, especially with the rapid antibody weaning (~5months) in this tropical setting."

Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Exploring the reported adverse effects of COVID-19 vaccines among vaccinated Arab populations: a multi-national survey study. (PubMed, Sci Rep) - "Johnson and Johnson, Sputnik Light, and Moderna vaccines showed the highest frequency of AEs...In conclusion, AEs were common among our participants, especially local AEs. Further extensive studies are needed to generate more generalizable data regarding the safety of different vaccines."

Adverse events • Journal • Infectious Disease • Musculoskeletal Pain • Novel Coronavirus Disease • Pain • Respiratory Diseases

Assessing the prevalence and patterns of COVID-19 vaccine side effects among Syrian adults: A cross-sectional study. (PubMed, Prev Med Rep) - "This study aimed to assess the prevalence and patterns of COVID-19 vaccine side effects among Syrian adults, with a focus on the AstraZeneca and Sputnik Light vaccines, in light of the low vaccination rate in Syria (below 18%) attributed to fear of side effects...Our study found that COVID-19 vaccines are well tolerated among the Syrian population, with short-term side effects that typically resolve within three days. These findings are expected to bolster vaccination rates through enhanced public confidence and acceptance."

Adverse events • Journal • Observational data • Infectious Disease • Novel Coronavirus Disease • Pain

The impact of geo-political socio-economic factors on vaccine dissemination trends: a case-study on COVID-19 vaccination strategies. (PubMed, BMC Public Health) - "The analysis revealed strong indicators that the nations which spend more on healthcare were the ones that had the best SARS-Cov-2 vaccination rollout. To further support decision-making in the future, countries should address the trust and sentiment of their citizens towards vaccination. For this, expenses need to be made to develop and promote vaccines and project them as positive health tools."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

TIKSAGEVIMAB/TSILGAVIMAB: EXPERIENCE OF USE FOR PRE-EXPOSURE PROPHYLAXIS OF COVID-19 IN ADULT PATIENTS WITH ONCOHEMATOLOGICAL DISEASES (EHA 2023) - "Spitnik V was used to vaccinate 26% (n=14) of patients and Sputnik Light was used to vaccinate 4,18% (n=2) of patients. According to our data, the use of tixagevimab/cilgavimab as a pre-contact prophylaxis of COVID-19 is not associated with loss / deterioration of hematological response after administration of the drug. Isolated non-hematological adverse events of mild severity have been reported. There were no episodes of severe COVID-19 after administration of tixagevimab/cilgavimab."

Clinical • Bone Marrow Transplantation • Cardiovascular • Hypertension • Infectious Disease • Novel Coronavirus Disease • Pulmonary Arterial Hypertension • Respiratory Diseases • Transplantation

Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies Level. (PubMed, Vaccines (Basel)) - "Thus, revaccination is most effective in individuals with an antibody level below 500 BAU/mL, regardless of the vaccinee age and COVID-19 contraction. For the first time, it has been shown that a single booster dose of the Sputnik vaccine is sufficient to form a protective immunity in most vaccinees regardless of age and preexisting antibody level."

Journal • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Sputnik Light and Sputnik V Vaccination Is Effective at Protecting Medical Personnel from COVID-19 during the Period of Delta Variant Dominance. (PubMed, Vaccines (Basel)) - "As expected, the highest effectiveness during this period was obtained in the group that received the third and fourth doses-96.5% (75.0-99.5%). The severity of COVID-19 in the vaccinated group was significantly lower than in the unvaccinated group."

Journal • Gynecology • Infectious Disease • Novel Coronavirus Disease • Obstetrics • Respiratory Diseases

COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 during Delta variant surge: a preliminary assessment from a case-control study in St. Petersburg, Russia. (PubMed, BMC Public Health) - "Our preliminary results show that in contrast to other Russian vaccines, Gam-COVID-Vac is effective against symptomatic SARS-CoV-2 infection caused by Delta VOC. Effectiveness is likely higher than the estimated 56% due to bias arising from high prevalence of the past COVID-19 in St. Petersburg."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review. (PubMed, Cochrane Database Syst Rev) - "Up to 6 December 2021, the majority of studies examined data on mRNA vaccines administered as standard vaccination schemes (two doses approximately four to eight weeks apart) that report on immunogenicity parameters or adverse events. Clinical outcomes were less commonly reported, and if so, were often reported as a secondary outcome observed in seroconversion or immunoglobulin titre studies. As informed by this scoping review, two effectiveness reviews (on haematological malignancies and kidney transplant recipients) are currently being conducted."

Journal • Review • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Multiple Sclerosis • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Rheumatology • Solid Tumor • Transplantation

Comparison of the Immunogenicity of five COVID-19 vaccines in Sri Lanka. (PubMed, Immunology) - "The Moderna vaccine elicited the highest ACE2 blocking antibody levels followed by Sputnik V/AZD1222, while those who received Sinopharm had the lowest levels. These findings highlight the need for further studies to understand the effects on clinical outcomes."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance. (PubMed, Vaccines (Basel)) - "The effectiveness in cases of more severe forms was higher than for less severe ones. Thus, present study indicates the high protective efficacy of vaccination against hospitalization with COVID-19 in case of Omicron lineage."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

SAFETY OF COVID-19 VACCINES IN PATIENTS WITH RHEUMATOID ARTHRITIS (PRELIMINARY DATA). (EULAR 2022) - "103 patients received disease-modifying antirheumatic drugs (54 - methotrexate, 30 - leflunomide, 10 - hydroxychloroquine, 8 - sulfasalazine, 1 - mofetil mycophenolate), 68 - biological drugs (58 - rituximab, 5 – TNF-α inhibitors, 4 - abatacept, 1 - tocilizumab), 64 - glucocorticoids, 10 - did not receive therapy...In the control group, 91 were vaccinated with Sputnik V, 16 with CoviVac, 6 with BNT162b2, 5 with Sputnik Light, 2 with EpiVacCorona, 1 with mRNA-1273 (114 participants received two components of the vaccine)... According to preliminary data, the tolerance of vaccines against COVID-19 in RA patients is satisfactory. Further studies are needed to study the safety, immunogenicity and clinical efficacy of immunization against COVID-19 in patients of this cohort."

Clinical • Immunology • Infectious Disease • Inflammatory Arthritis • Musculoskeletal Diseases • Musculoskeletal Pain • Novel Coronavirus Disease • Orthopedics • Pain • Rheumatoid Arthritis • Rheumatology

SAFETY OF VACCINES AGAINST COVID-19 IN PATIENTS WITH SPONDYLOARTHRITIS (PRELIMINARY DATA). (EULAR 2022) - "Objectives: To study the safety of COVID-19 vaccines in patients with SpA in real clinical practice...20 patients received disease-modifying antirheumatic drugs (12 - methotrexate, 8 - sulfasalazine), 10 - biological drugs (8 – TNF-ɑ inhibitors, 2 - IL-17 inhibitors), 6 - glucocorticoids, 1 - tofacitinib, 12 - only nonsteroidal anti-inflammatory drugs, 8 - did not receive therapy...In the control group 69 were vaccinated with Sputnik V, 15 - CoviVac, 5 - Sputnik Light and BNT162b2, 2 - EpiVacCorona, 1 - mRNA-1273... According to preliminary data, the tolerability of vaccines against COVID-19 in patients with SpA is satisfactory. Further studies with an increased sample are needed to study the safety, immunogenicity and clinical efficacy of immunization against COVID-19 in patients of this cohort."

Clinical • Ankylosing Spondylitis • Immunology • Infectious Disease • Inflammatory Arthritis • Musculoskeletal Pain • Novel Coronavirus Disease • Pain • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A

EFFICACY AND TOLERABILITY OF THE VACCINE AGAINST SARS- CoV-2 IN PATIENTS WITH SJOGREN’S SYNDROME RECEIVING VARIOUS TYPES OF THERAPY. (EULAR 2022) - "Rituximab (RTM) was administered in two 1000 mg infusions 14 days apart for the 1 st course, then 500 mg every 6 months...Five pts received single-dose rAd26 vector-based COVID-19 vaccine “Sputnik Light”, other 65 pts received 2 doses of Gam-COVID-Vac (Sputnik V)...20 pts at the time of vaccination received various immunosuppressive drugs: 1 – cyclophosphamide (CYC), 1 – leflunomide, 1 – Azathioprine, 3 – methotrexate, 2 - mycophenolate mofetil (MMF), 10 – hydroxychloroquine, 13 - low doses of methylprednisolone...In one case this syndrome required the prescription of dexamethasone... vaccination against SARS-CoV-2 infection was well tolerated by pts with SjS even in the absence of immunosuppressive therapy. In most cases, there were no exacerbation of the SjS and pts could continue immunosuppressive therapy without becoming infected COVID-19."

Clinical • Fibrosis • Hematological Malignancies • Immunology • Infectious Disease • Inflammatory Arthritis • Interstitial Lung Disease • Lymphoma • Novel Coronavirus Disease • Oncology • Pain • Pulmonary Disease • Respiratory Diseases • Rheumatology • Scleroderma • Sjogren's Syndrome • Systemic Sclerosis • Vasculitis • ERCC6

Review of COVID-19 viral vector-based vaccines and COVID-19 variants. (PubMed, Infez Med) - "The technology has been used to make Ebola vaccines and now COVID-19 vaccines...Current adenovirus vector-based vaccines being administered against SARS-CoV-2 infection are JNJ-78435735 by Johnson and Johnson (Janssen) along with Beth Israel Deaconess Medical Center, AZD1222 by Oxford-AstraZeneca, Sputnik V and Sputnik Light by Gamaleya Research Institute of Epidemiology and Microbiology, and Convidecia vaccine by CanSino Biologics...Efficacy against COVID-19 variants has been found in all but the Convidecia vaccine so far. Heterologous prime-boost COVID-19 vaccination regimen may be the new face and more efficient immunization approach for enhanced immunity against COVID-19."

Journal • Review • Cytomegalovirus Infection • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Boosting of the SARS-CoV-2-Specific Immune Response after Vaccination with Single-Dose Sputnik Light Vaccine. (PubMed, J Immunol) - "Additionally, we found a strong correlation between RBD-specific IgG titers and VNA in serum, and according to these data vaccination may be recommended when the RBD-specific IgG titers drop to 142.7 binding Ab units/ml or below. In summary, the results of the study demonstrate that vaccination is beneficial for both COVID-19-naive and recovered individuals, especially since it raises serum VNA against the B.1.617.2 variant, one of the five SARS-CoV-2 variants of concern."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine "Sputnik Light" for prevention of coronavirus infection in healthy adults. (PubMed, Lancet Reg Health Eur) - "The single-dose rAd26 vector-based COVID-19 vaccine "Sputnik Light" has a good safety profile and induces a strong humoral and cellular immune responses both in seronegative and seropositive participants. Russian Direct Investment Fund."

Clinical • Journal • P1/2 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8 • ERCC6 • IFNG

"UAE authorises Sputnik Light COVID-19 vaccine -Russia's RDIF https://t.co/pQ5M3ryb2l" (@Reuters)

Clinical • Infectious Disease • Novel Coronavirus Disease

"مقاله ای که در EClinicalMedicine (توسط مجله @TheLancet) منتشر شده است، به بررسی جزئیات اثربخشی واکسن Sputnik Light (اولین جزء SputnikV#) در بین 40،000 نفر در آرژانتین می پردازد. اثربخشی از 78.6-83.7% متغیر است که بیشتر از اکثر واکسن های دو جزئی است. https://t.co/QHpMAOkCUM" (@sputnik_ir)